NetworkNewsBreaks – Autolus Therapeutics plc (NASDAQ: AUTL) Featured in Mizuho Securities Research Report
Autolus Therapeutics plc (NASDAQ: AUTL) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate coverage of AUTL with a BUY rating and an $18 PT. AUTL's technology has shown the ability to deliver CAR-T with an enhanced safety profile, which we see as a unique and differentiating feature relative to commercially available products. We like the flexibility of the technology, the proximity to value-generating inflection points for the pipeline, and strong cash position. Our $18 PT is based a discounted NPV on revenue through 2029.” To request access to the…







